Repositioning CEP-1347, a chemical agent originally developed for the treatment of Parkinson’s disease, as an anti-cancer stem cell drug-Reference-Cited by-同舟云学术

Repositioning CEP-1347, a chemical agent originally developed for the treatment of Parkinson’s disease, as an anti-cancer stem cell drug

Published:2017-10-24 Issue:55 Volume:8 Page:94872-94882
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Okada Masashi¹,Takeda Hiroyuki¹²,Sakaki Hirotsugu¹³,Kuramoto Kenta¹,Suzuki Shuhei¹²,Sanomachi Tomomi¹²,Togashi Keita¹⁴,Seino Shizuka¹⁵,Kitanaka Chifumi¹⁵

Affiliation:

1. Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata 990-9585, Japan

2. Department of Clinical Oncology, Yamagata University School of Medicine, Yamagata 990-9585, Japan

3. Department of Obstetrics and Gynecology, Yamagata University School of Medicine, Yamagata 990-9585, Japan

4. Department of Ophthalmology, Yamagata University School of Medicine, Yamagata 990-9585, Japan

5. Research Institute for Promotion of Medical Sciences, Yamagata University Faculty of Medicine, Yamagata 990-9585, Japan

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting JNK kinase inhibitors via molecular docking: A promising strategy to address tumorigenesis and drug resistance;Bioorganic Chemistry;2024-12

2. CEP-1347 Boosts Chk2-Mediated p53 Activation by Ionizing Radiation to Inhibit the Growth of Malignant Brain Tumor Cells;International Journal of Molecular Sciences;2024-08-30

3. Selective Degradation of MLK3 by a Novel CEP1347-VHL-02 PROTAC Compound Limits the Oncogenic Potential of TNBC;Journal of Medicinal Chemistry;2024-08-29

4. CEP-1347 Dually Targets MDM4 and PKC to Activate p53 and Inhibit the Growth of Uveal Melanoma Cells;Cancers;2023-12-25

5. Identification of Potential Biomarkers associated with Prognosis and Pathogenesis of Pancreatic Cancer;2023-12-08